- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04255160
Impact of Estradiol on Endothelial Function in Peri-Menopausal Women
May 10, 2023 updated by: Megan M. Wenner, University of Delaware
The purpose of this study is to identify the impact of estradiol (E2) on the mechanisms that regulate vascular endothelial function in peri-menopausal (PERI) women.
This study is the first step in understanding factors contributing to endothelial dysfunction in women with advancing reproductive age and in response to E2 administration.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Cardiovascular disease (CVD) is the leading cause of death in women.
Although overall CVD-related mortality has declined, there has been an increase in CVD mortality in women aged 35-54 years, prior to menopause.
It is unclear what contributes to this increased mortality rate, and is a significant problem for women's health.
Endothelial function is considered a biomarker of cardiovascular health; declines in endothelial function are considered a precursor to the development of atherosclerosis and CVD.
Thus, changes in endothelial function in women as they advance through reproductive stages towards menopause may play a role in the greater prevalence of CVD mortality.
However, very few studies have focused on cardiovascular health in women leading up to menopause, during the PERI transition.
The PERI period is a critical time point where reproductive hormones and ovarian function change rapidly.
Recent data demonstrate that endothelial function begins to decline during PERI.
Furthermore, despite women being of similar biological age, significant differences in endothelial function were noted when classified based on reproductive age - specifically between early PERI and late PERI.
These data show that the decline initially occurs in the early PERI phase, making this a key time point for intervention to offset the future development of CVD.
Our central hypothesis is that increased Endothelin-1 (ET-1) and a loss of Endothelin-1 B (ETB) mediated vasodilation play a primary role in contributing to impaired endothelial function with advancing reproductive age.
We will assess macro- and micro- vascular endothelial function, assess intracellular ET-1 protein and ETB receptor expression in harvested endothelial cells from peripheral veins, and use the cutaneous circulation as an in vivo model to explore the receptor mechanisms (ETBR and ETAR) in early and late PERI in response to E2 or placebo.
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Megan M Wenner, PhD
- Phone Number: (302) 831-7343
- Email: mwenner@udel.edu
Study Contact Backup
- Name: Kathy Masso, BS
- Phone Number: (302) 831-3493
- Email: kcmasso@udel.edu
Study Locations
-
-
Delaware
-
Newark, Delaware, United States, 19716
- Recruiting
- University of Delaware
-
Contact:
- Megan M Wenner, PhD
- Phone Number: 302-831-7343
- Email: mwenner@udel.edu
-
Contact:
- Kathy Masso, BS
- Phone Number: 302-831-3493
- Email: kcmasso@udel.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
38 years to 56 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Peri-menopausal women between 40-58 years of age with variable cycles as defined by increase in cycle length of greater than 7 days within ten consecutive cycles, or amenorrhea for more than 2 months, but less than 12 months.
Exclusion Criteria:
- Women who are pregnant, planning on becoming pregnant, or are breast feeding;
- Women who have a history of cardiovascular disease, blood clots (e.g, pulmonary embolism or deep vein thrombosis), stroke, cancer, or liver disease;
- Women who have a body mass index less than 18 or greater than 35kg/m2;
- Women who use tobacco products;
- Women who's blood pressure is greater than 140/90 mmHg, have been diagnosed by a physician with hypertension or are taking medication for high blood pressure;
- Women who have a neurological disease, or diabetes;
- Women who have had a hysterectomy or have used hormones (birth control or hormone replacement) within the past 3 months;
- Women who have a latex allergy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
A placebo patch that is visually similar to the estradiol patch will be used for the group not receiving estradiol.
|
Experimental: Estradiol
Transdermal estradiol (0.1mg/day patch)
|
Transdermal estradiol (0.1mg/day patch) will be used by women for 7 days.
Administration of the patch will follow the package guidelines to change the patch after 3-4 days of use.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vascular Endothelial Function (Flow mediated dilation or FMD)
Time Frame: Change in FMD from Baseline to Day 7
|
The capacity of the large and small blood vessels to dilate.
|
Change in FMD from Baseline to Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endothelial Cell Protein Expression
Time Frame: Change in fluorescent intensity from Baseline to Day 7
|
Venous endothelial cells will be harvested from peripheral veins of women during the hormone intervention and stained for expression of ET-1 and ETB receptors.
|
Change in fluorescent intensity from Baseline to Day 7
|
Endothelin Receptor Responses
Time Frame: Change from Baseline to Day 7
|
The contribution of Endothelin A (ETA) and Endothelin B (ETB) receptors on changes in endothelial function will be assessed in the cutaneous circulation via microdialysis.
Blood flow responses to local heating will be assessed under control and blockade sites in women during estradiol or placebo administration.
|
Change from Baseline to Day 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2020
Primary Completion (Anticipated)
June 30, 2024
Study Completion (Anticipated)
June 30, 2025
Study Registration Dates
First Submitted
January 27, 2020
First Submitted That Met QC Criteria
February 1, 2020
First Posted (Actual)
February 5, 2020
Study Record Updates
Last Update Posted (Estimate)
May 11, 2023
Last Update Submitted That Met QC Criteria
May 10, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1508142
- R01HL146558 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vasodilation
-
Colorado State UniversityWithdrawnVasodilation | VasoconstrictionUnited States
-
Universidade Federal do Rio Grande (FURG)Completed
-
University of AlbertaRecruitingVasodilation | VasoconstrictionCanada
-
University of AlbertaCompletedVasodilation | VasoconstrictionCanada
-
University of AlbertaCompletedVasodilation | VasoconstrictionCanada
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedVasodilation | MethotrexateNetherlands
-
Columbia UniversityTerminated
-
Semmelweis UniversityCompletedVasodilation | Nitric Oxide | Oral Soft Tissue ConditionsHungary
-
University of MilanCompletedVasodilation | Vasoconstriction | Stretch | Sympathetic; ImbalanceItaly
-
Korea Ginseng CorporationNutrasource Pharmaceutical and Nutraceutical Services, Inc.RecruitingCardiovascular Diseases | Platelet Aggregation | Vasodilation | Blood Pressure DisordersUnited States
Clinical Trials on Estradiol (mylan or vivelle dot patch)
-
University of ChicagoJohns Hopkins University; Massachusetts General Hospital; Novo Nordisk A/S; University... and other collaboratorsTerminated
-
Massachusetts General HospitalCompleted
-
University of ChicagoTerminatedOsteoporosis | Osteopenia | Hypercalciuria | Hypercalciuria, Familial IdiopathicUnited States
-
Cedars-Sinai Medical CenterCompletedHypothalamic Amenorrhea | Estrogen Deficiency | Cardiovascular Disease (CVD)United States
-
Mayo ClinicCompleted
-
Northwestern UniversityUniversity of WashingtonCompletedCardiovascular Disease | Menopause | Postmenopause | PremenopauseUnited States
-
Massachusetts General HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedExercise-related AmenorrheaUnited States
-
University of DelawareAmerican Heart AssociationCompleted
-
Stanford UniversityCompletedOvarian Failure, PrematureUnited States
-
Massachusetts General HospitalThe Hospital for Sick Children; National Institute of Diabetes and Digestive...Completed